TOKYO, May 14 (Pulse News Wire) – HEALIOS K.K. (4593.T) reported a net loss of ¥2.659 billion for the first quarter of fiscal year 2026, compared to a loss of ¥3.460 billion in the same period last year.
Revenue declined by ¥30 million to ¥37.5 million due to increased sales expenses and general administrative costs. Operating profit was negative ¥757.7 billion, reflecting higher research and development expenditures of ¥320 million. The company's cash position improved significantly, reaching approximately ¥2.659 billion after raising additional funds through warrant exercises.
HEALIOS continues to advance its pipeline, with global phase three trials underway for its bone marrow-derived stem cell treatment, HLCM051, targeting acute respiratory distress syndrome (ARDS). Additionally, the company secured funding from the Ministry of Economy, Trade and Industry for manufacturing facilities aimed at enhancing production capacity. HEALIOS also entered into agreements with Minaris and JENECELL for the supply of conditioned media products, aiming to establish a stable supply chain.
Financial results showed a rise in financial income of ¥52 million but were offset by increased financial expenses of ¥552 million.
🟢 Confidence: High AI-translated content.